NCT00398996View on ClinicalTrials.gov

A Study to Compare Three Existing Starting Points of Anti-Retroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

642

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
HIV InfectionsTuberculosis
Interventions
DRUG

Early versus intermediate versus late initiation of ART

Initiation of once daily ddI (400 / 250mg), 3TC (300mg) and EFV (600mg)during the intensive phase of TB therapy or during the continuation phase of TB therapy or once TB therapy has been completed

Trial Locations (1)

4001

CAPRISA eThekwini Clinical Research Site, Durban

All Listed Sponsors
lead

Centre for the AIDS Programme of Research in South Africa

NETWORK

NCT00398996 - A Study to Compare Three Existing Starting Points of Anti-Retroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients | Biotech Hunter | Biotech Hunter